ECCO 2016: Dr Charlie Lees (Edinburgh, UK), Dr Ailsa Hart and Marian O’Connor (Harrow, UK), Dr James Lindsay (London, UK) and Dr Peter Irving (London, UK) discuss the new therapeutic landscape in IBD since changes to guidance by NICE and SMC over the last year
New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.
